Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ATALANTE-1
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
- NCT02654587 ↗
- Terminated
- OSE Immunotherapeutics
- Standard
We haven't built an HCP commentary report on ATALANTE-1 (OSE2101 in HLA-A2-positive advanced NSCLC after immune checkpoint inhibitor failure) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ATALANTE-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| YouTube | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- OSE2101; Docetaxel; Pemetrexed
- Arms
- OSE2101 · Experimental
- Docetaxel or Pemetrexed · Active comparator
- Enrollment
- 219
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- OSE Immunotherapeutics
- Start
- Feb 12, 2016
- Primary completion
- Jan 15, 2021
- Results posted
- Yes
- Registry record
- NCT02654587 · updated Feb 2, 2024
Publications
linked from the registry- Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G; ATALANTE-1 study group. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 Sep 11. PubMed 37704166